Frontlight ResearchEarly access
Prostate cancer trials in Poland
33 of 40 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 3Not yet taking people in PolandA clinical trial to learn more about the effects of AAA817 given with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer
- Where
- Gliwice, Warsaw
- Age
- 18 years and over
- People
- 199 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-512340-32-01 - Phase 1Taking peopleA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Where
- Bydgoszcz, Cracow, Koszalin, Warsaw
- Age
- 18 years and over
- People
- 453 worldwide
- Run by
- Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00 - Phase 3Taking peopleStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Where
- Bydgoszcz, Grudziądz, Kielce, Koszalin, Siedlce, Szczecin
- Age
- 18 years and over
- People
- 1,310 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136624 · EU 2023-504899-25-00 - Phase 1Taking peopleA Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
- Where
- Cracow, Gdansk, Katowice, Skorzewo
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00 - Phase 3Taking peopleA Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Where
- Bialystok, Bydgoszcz, Koszalin, Warsaw
- Age
- 18 years and over
- People
- 1,203 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07164443 · EU 2025-520927-26-00 - Phase 3Active, not recruitingA Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
- Where
- Cracow, Grudziądz, Koszalin, Lublin, Opole, Piotrkow Trybunalski, Torun, Warsaw, Wroclaw
- Age
- 18 years and over
- People
- 900 worldwide
- Run by
- Pfizer
See details and how to joinNCT06629779 · EU 2024-511652-40-00 - Phase 3Taking peopleA Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Where
- Bydgoszcz, Cracow, Katowice, Poznan, Siedlce, Warsaw
- Age
- 18 years and over
- People
- 1,440 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06925737 · EU 2024-517423-40-00 - Phase 1/2Taking peopleEIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
- Where
- Krakow, Lódz, Szczecin
- Age
- 18 years and over
- People
- 160 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00 - Phase 1/2Not yet taking people in PolandStudy of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
- Where
- Koszalin, Piotrkow Trybunalski, Przemyśl
- Age
- 18 years to 130 years
- People
- 283 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07181161 · EU 2024-520026-11-00 - Phase 3Not yet taking people in PolandAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Where
- Gdansk, Krakow, Warsaw
- Age
- 18 years and over
- People
- 670 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07611110 - Phase 2Taking people177Lu-PSMA as a Systemic Adjuvant Treatment in Patients With High and Very High Risk Prostate Cancer
- Where
- Gliwice
- Age
- 18 years and over
- People
- 200
- Run by
- Maria Sklodowska-Curie National Research Institute of Oncology
See details and how to joinNCT06449781 · EU 2023-504912-13-00 - Phase 3Taking peopleA Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
- Where
- Bialystok, Cracow, Gliwice, Kielce, Lodz, Lublin, Poznan, Siedlce, Skorzewo, Sosnowiec, Szczecin, Warsaw, Wroclaw
- Age
- 18 years and over
- People
- 736 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07365995 · EU 2025-524445-27-00 - Phase 3Not yet taking people in PolandSaruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
- Where
- Cracow, Gdansk, Koszalin, Lodz, Olsztyn, Poznan, Warsaw, Wroclaw
- Age
- 18 years and over
- People
- 1,330 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07711002 · EU 2026-526275-38-00 - Phase 3Taking peopleA Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Where
- Cracow, Gdynia, Gliwice, Koszalin, Piotrkow Trybunalski, Poznan, Rzeszow, Warsaw
- Age
- 18 years and over
- People
- 700 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00 - Phase 3Active, not recruitingThis Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Where
- Cracow, Gdynia, Koszalin, Lublin, Poznan, Rzeszow, Szczecin, Wroclaw, Wrocław
- Age
- 18 years and over
- People
- 1,000 worldwide
- Run by
- Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00 - Phase 1/2Active, not recruitingA Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- Where
- Gdansk, Koszalin, Poznan, Warsaw
- Age
- 18 years and over
- People
- 360 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06863272 · EU 2024-516036-94-00 - Phase 1/2Taking peopleAn Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
- Where
- Poznan
- Age
- 18 years and over
- People
- 188 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07206056 · EU 2025-521880-10-00 - Phase 1Taking peopleStudy of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Where
- Bydgoszcz, Gdansk, Otwock, Poznan, Wroclaw
- Age
- 18 years and over
- People
- 1,394 worldwide
- Run by
- Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00 - Phase 2Taking peopleStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Where
- Cracow, Gliwice, Warsaw
- Age
- 18 years to 130 years
- People
- 454 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00 - Phase 2Active, not recruitingA Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
- Where
- Gdansk, Gliwice, Myslowice, Otwock
- Age
- 18 years and over
- People
- 218 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07005154 · EU 2024-517653-27-00 - Phase 1Taking peopleStudy to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
- Where
- Cracow, Gdansk, Lodz, Poznan, Warsaw
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- Duke Street Bio Ltd
See details and how to joinNCT06458712 · EU 2023-508805-26-00 - Phase 1/2Not yet taking people in PolandA Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
- Where
- Cracow, Gdansk, Warsaw
- Age
- 18 years and over
- People
- 52 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07192614 · EU 2025-520626-37-00 - Phase 1/2Taking peopleA Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Where
- Gdansk, Poznan, Warsaw
- Age
- 18 years and over
- People
- 300 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04104776 · EU 2023-508002-20-00 - Phase 3Taking peopleA clinical study on SHR3680 combined with androgen deprived therapy (ADT) versus Bicalutamide combined with ADT in treatment of prostate cancer
- Where
- Piotrkow Trybunalski
- Age
- 18 years and over
- People
- 63 worldwide
- Run by
- Jiangsu Hengrui Pharmaceuticals Co. Ltd.
See details and how to joinNCT03520478 · EU 2024-515194-10-00 - No phaseTaking peopleTENS During Transperineal Prostate Biopsy
- Where
- Gdansk
- Age
- 40 years and over
- People
- 140
- Run by
- Medical University of Gdansk
See details and how to joinNCT07578324